RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket billFor Pfizer and it's US$43 Billion acquisition of Seagen and the subsequent invalidation of Seagen's U.S. Patent No. 10,808,039, which is the cornerstone of the trastuzumab-deruxtecan ADC product, [ comprised of an anti-human HER2 (anti-HER2) antibody, an enzymatically cleavable peptide-linker, and a proprietary topoisomerase I inhibitor payload (exatecan derivative or DX-8951 / DXd)] - the implication for Pfizer is that under the proposed USPTO rule, “if you invalidate one, the whole thing falls,” Pfizer's right to its trastuzumab-deruxtecan ADC product will need to now be under license to Daiichi-Sanyo, thus eliminating Pfizer's 'freedom to operate' in the antibody-drug conjugate market space.
Pfizer will now need to expand its product portfolio to extend beyond the HER2 ADC portfolio that it acquired in the US$43 Billion Seagen acquisition.